Pre-diagnosis and pre-treatment attritions among presumptive MDR/RR-TB patients in Chonburi province, Thailand, 2015-2017 10.55131/jphd/2022/200305
Article Sidebar
Main Article Content
Abstract
The low detection rate of multidrug-resistant tuberculosis (MDR-TB) is one of the major obstacles to TB control in Thailand. Thus, this study aimed to assess pre-diagnosis and pre-treatment attrition rates among patients suspected of having MDR-TB, identify factors related to pre-diagnosis attrition, and determine the turnaround times (TAT) of diagnosis and treatment pathway. A retrospective cohort analysis was conducted using a record review. Among 972 presumptive MDR-TB patients, only 354 (36.4%) underwent drug-susceptibility testing (DST). Multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) was found in 32 patients, consisting of 26 (81.2%) males and 6 (18.8%) females. Pre-diagnosis and pre-treatment attrition rates were 63.58 % and 28.1%, respectively. Furthermore, the median (interquartile range [IQR]) turnaround time for MDR-TB testing was seven days (IQR 0-62 days), and the median time to the start of MDR-TB treatment was 20 days (IQR 2-38 days). Meanwhile, the factors associated with pre-diagnosis attrition were migrants, presumptive TB cases presenting at secondary-level hospitals, TB patients identified from hospitals outside the Ministry of Public Health, and extrapulmonary TB cases. The results of this research demonstrated that only one-third of patients at risk of MDR-TB underwent DST. Therefore, it is essential for healthcare workers at all levels to be educated and trained to identify patients that are eligible for DST. In addition, other interventions such as the decentralization of laboratory services and MDR-TB treatment to secondary-care district hospitals are also urgently needed.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
World Health Organization. Global tuberculosis report 2020: executive summary [Internet]. [cited 2021 Feb 22]. Available from: https://apps. who. int/iris/bitstream/handle/10665/ 337538/9789240016095-eng.pdf
World Health Organization. Global tuberculosis report 2019 [Internet]. [cited 2021 Feb 22]. Available from: https://apps.who.int/iris/handle/10665/329368
World Health Organization. WHO consolidated guidelines on tuberculosis Module 4: treatment: Drug-resistant TB treatment [Internet]. [cited 2021 Feb 22]. Available from: https://www. paho.org/en/documents/who-consolidated-guidelines-tuberculosis-
module-4-treatment-drug-resistant-tuberculosis
World Health Organization. Thailand TB country profile [Internet]. [cited 2021 Jan 2]. Available from: https:// www.aidsdatahub.org/sites/default/files/resource/who-thailand-tb-
country-profile-2019.pdf.
Department of Disease Control. TBcm Data Center [Internet]. [cited 2018 Jun 20]. Available from: http:// 122.155.219.72/tbdc/frontend/web/index.php
World Health Organization. Implementing tuberculosis policy framework [Internet]. [cited 2020 Sept 10]. Available from: https://apps.who. int/iris/bitstream/handle/10665/ 162712/9789241508612eng.pdf?sequence=1
Khann S, Mao ET, Rajendra YP, Satyanarayana S, Nagaraja SB, Kumar AM V. Linkage of Presumptive Multidrug Resistant Tuberculosis (MDR-TB) Patients to Diagnostic and Treatment Services in Cambodia. PLoS One 2013;8: e59903. doi: 10.1371/ journal.pone.0059903
Shewade HD, Kokane AM, Singh AR, Verma M, Parmar M, Chauhan A, et al. High pre-diagnosis attrition among patients with presumptive MDR-TB: an operational research from Bhopal district, India. BMC Health Serv Res 2017;17:249. doi: 10.1186/s12913-017-2191-6.
Shewade HD, Govindarajan S, Sharath BN, Tripathy JP, Chinnakali P, Kumar AM V, et al. MDR-TB screening in a setting with molecular diagnostic techniques: who got tested, who didn’t and why?. Public Heal Action 2015; 5:132-139. doi: 10.5588/ pha.14.0098
Hossain ST, Isaakidis P, Sagili KD, Islam S, Islam Md A, Shewade HD, et al. The Multi-Drug Resistant Tuberculosis Diagnosis and Treatment Cascade in Bangladesh. PLoS One
;10: 0129155. doi:10.1371/ journal.pone.0129155
Charambira K, Ade S, Harries AD, Ncube RT, Zishiri C, Sandy C, et al. Diagnosis and treatment of TB patients with rifampicin resistance detected using Xpert(®) MTB/RIF in Zimbabwe. Public Health Action 2016; 6:122–128. doi:10.5588/pha.16.0005
Ministry of Public Health. Thailand Operational Plan to End TB 2017-2021.
Bangkok: MOPH. 2017.
Becton Dickinson and Company. BD BACTEC™ MGIT™ 960 Mycobacteria Culture System [Internet]. [cited 2022 Apr 6]. Available from: https://www.bd.com/documents/ bd-legacy/patient-education/diabetes-care/BD_BACTEC-MGIT_PE_TR.pdf
Cepheid company. Xpert® MTB/RIF Raising the Standard for Tuberculosis Diagnosis [Internet]. [cited 2022 Apr 6]. Available from: https://www. cepheid.com/en/tests/Critical-Infectious-Diseases/Xpert-MTB-RIF
Bureau of Tuberculosis. Reach-Recruit-Test-Treat-Retain: RRTTR (Stop TB and AIDS through RTTR: STAR). Bangkok:Aksorn Graphic & Design Publishing. 1995.
Bureau of Tuberculosis. National Tuberculosis Control Programme Guideline, Thailand. Bangkok: Graphic Arts & Design Company. 2018.
Shewade HD, Nair D, Klinton JS, Parmar M, Lavanya J, Murali L, et al. Low pre-diagnosis attrition but high pre-treatment attrition among patients with MDR-TB: An operational research from Chennai, India. J Epidemiol Glob Health. 2017;7 :227–33. doi: 10.1016/ j.jegh.2017.07.001
Abeygunawardena SC, Sharath BN, Van den Bergh R, Naik B, Pallewatte N, Masaima MNN. Management of previously treated tuberculosis patients inKalutara district, Sri Lanka: how are we faring? Public Health Action 2014,4:105–109. doi:10.5588/pha.13. 0111.
Shewade HD, Govindarajan S, Thekkur P, Palanivel C, Muthaiah M, Kumar AM V, et al. MDR-TB in Puducherry, India: reduction in attrition and turnaround time in the diagnosis
and treatment pathway. Public Health Action 2016;6(4):242–246. doi: 10.5588/pha.16.0075.
Harries AD, Michongwe J, Nyirenda TE, Kemp JR, Squire SB, Ramsay AR, et al. Using a bus service for transporting sputum specimens to the Central Reference Laboratory: effect on the routine TB culture service in Malawi. Int J Tuberc Lung Dis 2004;8(2):204–210.
Qi W, Harries AD, Hinderaker SG. Performance of culture and drug susceptibility testing in pulmonary tuberculosis patients in northern China. Int J Tuberc Lung Dis. 2011; 15: 137–9.
Kilale AM, Ngowi BJ, Mfinanga GS, Egwaga S, Doulla B, Kumar AM V., et al. Aresputum samples of retreatment tuberculosis reaching the reference laboratories? A 9-year audit in Tanzania. Public Health Action. 2013;3(2) 0:156–159. doi: 10.5588/ pha.12.0103
Soontornmon K, Boonthanapat N, Panya L, Thongsuk P, Monkongdee P, Watanatorn S, et al. Assessment of system barriers in MDR-TB management: a case study in a provincial hospital in Lopburi, Thailand. J Heal Sci [Internet]. 2017; 26(4). [cited 2020 Sept 10]. Available from:http://thailand.digitaljournals.org/ tdj/index.php/JHS/article/viewFile/34/33
Health Information System Development Office. Migrant Workers and Thailand’s Health Security System [Internet]. [cited 2019 Oct 6]. Available from: http://www.hiso.or.th/hiso/ picture/reportHealth/ThaiHealth2013/eng2013_26.pdf
Tanvejsilp P, Loeb M, Dushoff J, Xie F. Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand. Pharmaco Economics – Open [Internet]. [cited 2019 September 2]. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6103926/
Singla N, Satyanarayana S, Sachdeva KS, Van Den Bergh R, Reid T, Tayler-Smith K, et al. Impact of introducing the line probe assay on time to treatment initiation of MDR-TB in Delhi, India. PLoS One 2014;9:5–9. doi: 10.1371/ journal.pone.0102989
Shewade HD, Shringarpure KS, Parmar M, Patel N, Kuriya S, Shihora S, et al. Delay and attrition before treatment initiation among MDR-TB patients in five districts of Gujarat, India. Public Heal action. 2018;8:59–65. doi.org/ 10.5588/pha.18.0003
Chadha SS, BN S, Reddy K, Jaju J, PH V, Rao S, et al. Operational Challenges in Diagnosing Multi-Drug Resistant TB and Initiating Treatment in Andhra Pradesh, India. PLoS One 2011;6(11): e26659.doi:10.1371/journal.pone.002665929.
Turaev, L, Kumar, A, Nabirova, D, Alaverdyan, S, Parpieva, N, & Abdusamatova, B. Universal access to Xpert MTB/RIF Testing for Diagnosis of Tuberculosis in Uzbekistan: How well are we doing?. Int J Environ Res Public Health 2021;18,2915. doi: doi.org/10.3390/ijerph18062915.